Test your knowledge of evolving treatment options for patients with lung metastasis and HER2-low status
{"name":"Test your knowledge of evolving treatment options for patients with lung metastasis and HER2-low status", "url":"https://www.quiz-maker.com/QJ6A98YK7","txt":"The KEYNOTE-522 trial showed that a patient with early triple-negative breast cancer could experience longer event-free survival with neoadjuvant pembrolizumab plus chemotherapy and surgery if it’s followed by what drug?, An IHC level of 1+ or 2+ is considered HER2-low., The DESTINY-BREAST04 study showed that up to 12% of patients with HER2-low who took trastuzumab deruxtecan developed which of the following adverse events?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}